1 hour ago
1
Andrii Dodonov
Regeneron Pharmaceuticals (NASDAQ:REGN) announced on Tuesday that a Phase 3 trial for its RNA-based therapy cemdisiran, developed with Alnylam Pharmaceuticals (NASDAQ:ALNY), succeeded in a late-stage trial for generalized myasthenia gravis, a rare autoimmune disorder.
According to the company, cemdisiran, as a monotherapy
English (US) ·